Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Current Leases: 2019-2024

Historic Current Leases for Rocket Pharmaceuticals (RCKT) over the last 6 years, with Dec 2024 value amounting to $1.9 million.

  • Rocket Pharmaceuticals' Current Leases rose 2.99% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year increase of 2.99%. This contributed to the annual value of $1.9 million for FY2024, which is 3.63% up from last year.
  • According to the latest figures from FY2024, Rocket Pharmaceuticals' Current Leases is $1.9 million, which was up 3.63% from $1.8 million recorded in FY2023.
  • Rocket Pharmaceuticals' Current Leases' 5-year high stood at $1.9 million during FY2024, with a 5-year trough of $1.6 million in FY2020.
  • Moreover, its 3-year median value for Current Leases was $1.8 million (2023), whereas its average is $1.8 million.
  • Data for Rocket Pharmaceuticals' Current Leases shows a peak YoY surged of 71.79% (in 2020) over the last 5 years.
  • Rocket Pharmaceuticals' Current Leases (Yearly) stood at $1.6 million in 2020, then increased by 2.74% to $1.7 million in 2021, then rose by 2.78% to $1.7 million in 2022, then rose by 3.17% to $1.8 million in 2023, then rose by 3.63% to $1.9 million in 2024.